Patterns of response to anti‐calcitonin gene‐related peptide monoclonal antibodies during first 6 months of treatment in resistant migraine patients: Impact on outcome

Key Points

Key points are not available for this paper at this time.

Abstract

Initial response to anti-CGRP MAbs is not consistent in all patients. Persistence of anxiety and depression might be associated with lower response rates at M6.

Bookmark

Cite This Study

Torres‐Ferrús et al. (Tue,) studied this question.

synapsesocial.com/papers/69d709f041375cf86eed8f48 https://doi.org/https://doi.org/10.1111/ene.15816

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study2021 · 109 citations
2Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing2020 · 50 citations
3European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update2022 · 447 citations
4<b>mice</b>: Multivariate Imputation by Chained Equations in<i>R</i>2011 · 13,548 citations
5An inventory for measuring clinical anxiety: Psychometric properties.1988 · 10,940 citations